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PPLLSG transplant centers: within
PPLLSG three transplant centers are ac-
tive, i.e. in Poznan (since 1989), in Wrodaw
(since 1994) and in Lublin (since 1998).
No. of transplant rooms: number
of transplant rooms was growing from
1 in 1989 to 19 in 2000 (12 in Wrodaw,
4 in Lublin, 3 in Poznan).
No. of patients and type (allo/auto)
of HSCT per year: 1989 - 1/0 (Poznan);
1990 to 1992 - 5/0 (Poznan); 1993 - 6/0
(Poznan); 1994 - 12 (1/5 in Wrodaw,
6/0 in Poznan); 1995 - 17 (1/6 in Wroclaw,
1% in Poznan); 1996 - 34 (9/15 in Wro-
claw, 1% in Poznan); 1997 - 37 (5/21
in Wroclaw, 11/0 in Poznan); 1998 - 45
(8/21 in Wroclaw, 14/0 in Poznan, 0/2
in Lublin); 1999 - 66 (14/16 in Wrodaw,
1/19 in Lublin, 16/0 in Poznan); 2000 - 84
(22/21 in Wrodaw, 16/5 in Poznan, 6/14
in Lublin). Total number of patients and ty-
pe of transplant: 317 [allo 172 (54,3%)/
auto 145 (45,7%)].
Indications for allo-HSCT: ALL 62
(36,0%), AML 31 (18,0%), CML 25
(14,5%), SAA 20 (11,6%), MDS 13 (7,6%),
B-DA 6 (3,5%), NHL 5 (2,9%), SCID 5
(2,9%), FA 4 (2,3%), Ewing s. 1 (0,6%),
i.e. malignant diseases 137 (79,7%)
and non-malignant diseases 35 (20,3%)
(congenital 15, acquired 20).
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Indications for auto-HSCT: NHL 39
(26,9%), ALL 21 (14,5%), AML 21 (14,5%),
RMS 16 (11,0%), NBL 15 (10,3%), Ewing
s. 11 (7,6%), HD 9 (6,2%), CML 2 (1,4%),
other solid tumors 11 (7,6%), i.e. leukemia
+ lymphoma 92 (63,4%) and solid tumors
53 (36,6%).
Stem cell sources for allo-HSCT: BM
152 (88,4%), PBSC 17 (79,9%) - in Wro-
daw since 1996, BM+PBSC 2 (1,2%), CB 1
(0,6%) - in Poznan since 2000.
Stem cell sources for auto-HSCT: PBSC
124 (85,5%), BM+PBSC 15 (10,3%), BM 6
(4,1%).
Donor type for allo-HSCT: MSD 148
(86,0%), MMRD 18 (10,5%) - in Wrodaw
since 1996, MUD 6 (3,5%) - in Wrodaw
since 2000.
Conclusion: There was significant de-
velopment of HSCT within PPLLSG cen-
ters in the nineties. However, in context
of 1500 new cases of cancer diagnosed
and treated each year in these centers as
well as in context of contemporary role
of HSCT in cancer therapy in children,
the number of auto- and allo-HSCT
(especially from alternative donors
and from alternative sources) performed
in pediatric centers is still too low. Further
increase of HSCT number is necessary
to fulfil therapeutical standards and to im-
prove treatment results in Polish children
with cancer.
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